Pricing Log in Create free account

Biogen Inc. (BIIB) vs Novo Nordisk A/S (NVO)

Biogen Inc. and Novo Nordisk A/S are both Drug Manufacturers General companies. Novo Nordisk A/S is the larger, with a market value of $134.8B against $36.1B — 3.7× the size. Novo Nordisk A/S trades at the lower P/E: 10.1× against 105×. Novo Nordisk A/S grew revenue faster over the last twelve months: 11.1% against 2.30%. Novo Nordisk A/S has the higher net margin (34.1% vs 3.37%) and the higher return on invested capital (29.6% vs 1.94%). Across the 22 metrics below, Novo Nordisk A/S leads on 16 and Biogen Inc. on 6.

Valuation

Metric BIIB NVO Drug Manufacturers General median
P/E 105.24 10.12 26.51
P/S 3.57 3.41 3.49
P/B 1.94 5.28 5.28
Price to free cash flow 21.67 25.76 21.67
EV/EBITDA 18.65 6.99 14.73
EV/Sales 4.15 3.67 4.15
Earnings yield 0.95% 9.88% 2.41%
Free cash flow yield 4.61% 3.88% 4.07%

Profitability

Metric BIIB NVO Drug Manufacturers General median
Gross margin 73.96% 80.89% 73.01%
Operating margin 7.53% 42.66% 18.34%
Net margin 3.37% 34.09% 7.31%
Free cash flow margin 16.45% 13.25% 18.56%
Return on equity 1.87% 58.84% 5.80%
Return on assets 1.13% 20.52% 2.28%
Return on invested capital 1.94% 29.63% 6.26%

Growth

Metric BIIB NVO Drug Manufacturers General median
Revenue growth (TTM) 2.30% 11.14% 6.72%
EPS growth (last fiscal year) (21.38%) 6.40% 21.81%
Revenue growth, 5-year CAGR (5.96%) 19.20% 4.75%
Net income growth, 5-year CAGR (20.22%) 19.16% 0.00%

Health

Metric BIIB NVO Drug Manufacturers General median
Debt to equity 0.39 0.62 0.62
Current ratio 1.95 0.84 1.39
Net debt to EBITDA 0.84 0.65 1.15

Dividend

Metric BIIB NVO Drug Manufacturers General median
Dividend yield — 4.46% 2.32%
Payout ratio — 0.45 0.59

Size

Metric BIIB NVO Drug Manufacturers General median
Market cap 36.06b 134.84b 129.04b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack